Calendar

pharmadog

Week of Apr 27, 2026

Apr 30, 2026phase 1 2 completion84d agoNovartis AG — zigakibart (Phase I/II Trial Completion)zigakibart

Therapy area: Genito Urinary System. Indication: IgA Nephropathy (Berger's Disease)

full page →zigakibart →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoAmsterdam UMC — tremelimumab (Phase I/II Trial Completion)tremelimumab

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

full page →tremelimumab →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoInstitute of Hematology & Blood Diseases Hospital — cyclophosphamide (Phase I/II Trial Completion)cyclophosphamide

Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

full page →cyclophosphamide →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoZhejiang Doer Biologics Corp — DR-30206 (Phase I/II Trial Completion)DR-30206

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Colorectal Cancer, Gastrointestinal Tumor, Metastatic Colorectal Cancer

full page →DR-30206 →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoUnity Health Toronto — bupivacaine (Phase I/II Trial Completion)bupivacaine

Therapy area: Musculoskeletal Disorders. Indication: Osteoarthritis

full page →bupivacaine →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoHenan Provincial People's Hospital — ofatumumab (Phase I/II Trial Completion)ofatumumab

Therapy area: Central Nervous System. Indication: Neuromyelitis Optica (Devic's Syndrome)

full page →ofatumumab →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoDuke University — deferiprone (Phase I/II Trial Completion)deferiprone

Therapy area: Cardiovascular, Central Nervous System. Indication: Cerebral Aneurysms, Dementia, Stroke, Subarachnoid Hemorrhage

full page →deferiprone →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoLepu Biopharma Co Ltd — pucotenlimab (Phase I/II Trial Completion)pucotenlimab

Therapy area: Oncology. Indication: Pancreatic Cancer

full page →pucotenlimab →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoJiangsu Hengrui Pharmaceuticals Co Ltd — adebrelimab (Phase I/II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoMultitude therapeutics Inc — AMT-253 (Phase I/II Trial Completion)AMT-253

Therapy area: Non Malignant Disorders, Oncology. Indication: Acral Lentiginous Melanoma, Cervical Cancer, Endometrial Cancer, Gynecological Cancer, Leiomyosarcoma, Melanoma, Metastatic Melanoma, Solid Tumor, Uterine Leiomyoma (Uterine Fibroids)

full page →AMT-253 →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoBayer AG — avelumab (Phase I/II Trial Completion)avelumab

Therapy area: Oncology. Indication: Bone Metastasis, Malignant Neoplasms, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostate Cancer

full page →avelumab →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoAbbVie Inc — venetoclax (Phase I/II Trial Completion)venetoclax

Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Leukemia, Leukemia, T-Cell Leukemia

full page →venetoclax →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoAstraZeneca Plc — Calquence (Phase I/II Trial Completion)CALQUENCE

Therapy area: Oncology. Indication: CNS Lymphoma, Diffuse Large B-Cell Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma

full page →CALQUENCE →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoHenan Cancer Hospital — methotrexate (Phase I/II Trial Completion)Maxtrex

Therapy area: Oncology. Indication: Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Lung Cancer

full page →Maxtrex →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoArvinas Inc — samuraciclib (Phase I/II Trial Completion)samuraciclib

Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

full page →samuraciclib →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoChiba Cancer Center — nivolumab (Phase I/II Trial Completion)nivolumab

Therapy area: Oncology. Indication: Adenoid Squamous Cell Carcinoma (Pseudoglandular Squamous Cell Carcinoma), Basaloid Squamous Cell Carcinoma, Esophageal Cancer, Squamous Cell Carcinoma

full page →nivolumab →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoNational Cheng-Kung University Hospital — cisplatin (Phase I/II Trial Completion)cisplatin

Therapy area: Oncology. Indication: Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC)

full page →cisplatin →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoImplicit Bioscience Ltd — Atibuclimab (Phase I/II Trial Completion)Atibuclimab

Therapy area: Cardiovascular. Indication: Acute Decompensated Heart Failure, Congestive Heart Failure (Heart Failure)

full page →Atibuclimab →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoNakornping Hospital — bupivacaine (Phase I/II Trial Completion)bupivacaine

Therapy area: Central Nervous System. Indication: Post-Operative Pain

full page →bupivacaine →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoCentre International de Développement Pharmaceutique — afamelanotide (Phase I/II Trial Completion)afamelanotide

Therapy area: Dermatology. Indication: Vitiligo

full page →afamelanotide →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoEyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)MK-8748

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Diabetic Macular Edema, Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration

full page →MK-8748 →source: globaldata

Apr 30, 2026phase 1 2 completion84d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

full page →M-701 →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoNational Cancer Institute US — PEP-CMV (Phase I/II Trial Initiation)PEP-CMV

Therapy area: Oncology. Indication: Ependymoma, Glioma, High-Grade Glioma, Medulloblastoma

full page →PEP-CMV →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoSichuan Kelun Pharmaceutical Co Ltd — SKB-103 (Phase I/II Trial Initiation)SKB-103

Therapy area: Oncology. Indication: Solid Tumor

full page →SKB-103 →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoRemeGen Co Ltd — RC-288 (Phase I/II Trial Initiation)RC-288

Therapy area: Oncology. Indication: Melanoma, Non-Small Cell Lung Cancer, Prostate Cancer, Small-Cell Lung Cancer, Solid Tumor

full page →RC-288 →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoFennec Pharmaceuticals Inc — sodium thiosulfate (Phase I/II Trial Initiation)sodium thiosulfate

Therapy area: Ear Nose Throat Disorders, Oncology. Indication: Esophageal Cancer, Head And Neck Cancer, Hearing Disorders, Lung Cancer, Malignant Pleural Mesothelioma, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor)

full page →sodium thiosulfate →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoDartsbio Pharmaceutical (Guangdong) Co Ltd — DS-010 (Phase I/II Trial Initiation)DS-010

Therapy area: Musculoskeletal Disorders, Oncology. Indication: Cachexia, Cancer Anorexia-Cachexia Syndrome, Solid Tumor

full page →DS-010 →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoInstitute of Hematology & Blood Diseases Hospital — azacitidine (Phase I/II Trial Initiation)Onureg

Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome (Preleukemia)

full page →Onureg →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoBeijing Bethune Charitable Foundation — bevacizumab (Phase I/II Trial Initiation)bevacizumab

Therapy area: Oncology. Indication: Hepatocellular Carcinoma

full page →bevacizumab →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoBeijing Eastern Biotech Co Ltd — JY-016 (Phase I/II Trial Initiation)JY-016

Therapy area: Oncology. Indication: Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Recurrent Head And Neck Squamous Cell Carcinoma, Solid Tumor

full page →JY-016 →source: globaldata

Apr 30, 2026phase 1 2 initiation84d agoCompass Therapeutics Inc — CTX-471 (Phase I/II Trial Initiation)CTX-471

Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Glioma, Recurrent Glioblastoma Multiforme (GBM)

full page →CTX-471 →source: globaldata

Apr 30, 2026phase 2 completion84d agoUsynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)UA-021

Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

full page →UA-021 →source: globaldata

Apr 30, 2026phase 2 completion84d agoCairo University — lidocaine (Phase II Trial Completion)LIDOCAINE

Therapy area: Central Nervous System. Indication: Post-Operative Pain

full page →LIDOCAINE →source: globaldata

Apr 30, 2026phase 2 completion84d agoVeer Chandra Singh Garhwali Government Medical Science and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

Therapy area: Ear Nose Throat Disorders. Indication: Otitis Media

full page →bupivacaine →source: globaldata

Apr 30, 2026phase 2 completion84d agoUniversity of Benin Teaching Hospital — doxycycline (Phase II Trial Completion)doxycycline ER

Therapy area: Women's Health. Indication: Unspecified Gynecological Disorders

full page →doxycycline ER →source: globaldata

Apr 30, 2026phase 2 completion84d agoVaidya Yagya Dutt Sharma Ayurvedic P. G. Mahavidhyalaya — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

Therapy area: Dermatology. Indication: Burns

full page →ayurvedic medicine →source: globaldata

Apr 30, 2026phase 2 completion84d agoGandhi Medical College & Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

Therapy area: Oncology. Indication: Malignant Neoplasms

full page →dexmedetomidine →source: globaldata

Apr 30, 2026phase 2 completion84d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →telitacicept →source: globaldata

Apr 30, 2026phase 2 completion84d agoDalian Municipal Central Hospital — dexamethasone (Phase II Trial Completion)dexamethasone

Therapy area: Central Nervous System. Indication: Post-Operative Pain

full page →dexamethasone →source: globaldata

Apr 30, 2026phase 2 completion84d agoSmt.B.K.Shah Medical Institute & Research Centre & Dhiraj Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

Therapy area: Central Nervous System. Indication: Sedation

full page →dexmedetomidine →source: globaldata

Apr 30, 2026phase 2 completion84d agoKSO Corp — undisclosed plant extract (Phase II Trial Completion)undisclosed plant extract

Therapy area: Genito Urinary System. Indication: Unspecified Genito Urinary Disorders

full page →undisclosed plant extract →source: globaldata

Apr 30, 2026phase 2 completion84d agoThe First Affiliated Hospital of Guangxi Medical University — fospropofol disodium (Phase II Trial Completion)fospropofol disodium

Therapy area: Central Nervous System. Indication: Sedation

full page →fospropofol disodium →source: globaldata

Apr 30, 2026phase 2 completion84d agoQinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Gastrointestinal, Infectious Disease. Indication: Gastritis, Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

Apr 30, 2026phase 2 completion84d agoQilu Pharmaceutical Co Ltd — iruplinalkib (Phase II Trial Completion)iruplinalkib

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

full page →iruplinalkib →source: globaldata

Apr 30, 2026phase 2 completion84d agoTufts Medical Center — phytonadione (Phase II Trial Completion)PHYTONADIONE

Therapy area: Musculoskeletal Disorders. Indication: Osteoarthritis

full page →PHYTONADIONE →source: globaldata

Apr 30, 2026phase 2 completion84d agoDanone Research & Innovation — (prebiotics + probiotic + protein blend + micronutrient blend) (Phase II Trial Completion)(prebiotics + probiotic + protein blend + micronutrient blend)

Therapy area: Central Nervous System, Metabolic Disorders. Indication: Ageing, Unspecified Psychiatric Disorders

full page →(prebiotics + probiotic + protein blend + micronutrient blend) →source: globaldata

Apr 30, 2026phase 2 completion84d agoNational Health and Medical Research Council — docosahexaenoic acid (Phase II Trial Completion)docosahexaenoic acid

Therapy area: Women's Health. Indication: Labor And Delivery

full page →docosahexaenoic acid →source: globaldata

Apr 30, 2026phase 2 completion84d agoChildren’s Hospital of Chongqing Medical University — iKids-Growth (Phase II Trial Completion)iKids-Growth

Therapy area: Hormonal Disorders. Indication: Shox Deficiency

full page →iKids-Growth →source: globaldata

Apr 30, 2026phase 2 completion84d agoRegeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)cemiplimab

Therapy area: Oncology. Indication: Adenocarcinoma, Colon Cancer, Colorectal Cancer

full page →cemiplimab →source: globaldata

← prev

page 12 of 156

Week of Apr 27, 2026